Amyotrophic lateral sclerosis (ALS) is a severe neurodegenerative disease characterized by the progressive loss of motor neurons — nerve cells that control the voluntary muscles. This leads to symptoms including overall muscular weakness, causing difficulties with moving, breathing, eating, and speaking.
ALS has no cure at present, but there are treatments to help manage the condition. Medications are available to help ease specific disease symptoms. The U.S. Food and Drug Administration (FDA) has approved two treatments that specifically aim to slow the progression of ALS: Rilutek (riluzole) and Radicava (edaravone). Rilutek has also been approved in Canada, Australia, and across Europe; the approval of Radicava is still under review in many countries.
Neither Rilutek nor Radicava has been shown to reverse the damage already caused by ALS, but it is thought that they might increase patients’ life expectancy. They are often taken in combination with symptomatic treatments to improve a patient’s quality of life.
Rilutek was approved by the FDA in 1995 as the first systemic treatment to slow ALS progression and prolong survival. It remained the sole systemic ALS therapy in the U.S for more than 20 years, until Radicava became available.
Other countries have since approved the therapy to treat ALS. For example, Rilutek has been approved in Europe by the European Medicines Agency (EMA) since 1996.
Rilutek is thought to prevent an excessive release (buildup) of glutamate, a neurotransmitter or cell- signaling molecule thought to rise to toxic levels in the brain and spinal cord of an ALS patient, damaging nearby nerve cells. By reducing this buildup, it is thought that Rilutek prevents or slows the glutamate-induced deterioration of motor neurons.
Radicava, approved by the FDA in May 2017, is administered as an injection into a vein. Radicava was also approved for marketing by Health Canada as of October 2018. In Japan and South Korea, edaravone has been marketed under the brand name Radicut since 2015.
While Radicava is not yet available in Europe, the EMA accepted a new filing for edaravone on May 24, 2018, to consider marketing authorization. Radicava is not currently available in Australia, and no application has been made to the Therapeutic Goods Administration (TGA) for its approval.
Radicava is thought to work through a different process than Rilutek, although its exact mechanism of action is not fully understood. It is thought to act as an antioxidant or a so-called free radical scavenger. Free radicals are formed as a byproduct of energy production by the cell. Normally, free radicals are quickly removed by the body; if not, they can cause damage and lead to cell death through a process called oxidative stress, defined as an imbalance between free radical production and the antioxidants that work to neutralize them. Damage from free radicals is thought to be one of the mechanisms in the progressive nerve cell death that marks ALS. It is thought that by helping to remove free radicals quickly, Radicava can reduce damage to the nervous system and slow disease progression.
ALS News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.